AAN.com
×
Site maintenance Tuesday, May 28, 2024. Please note that new registrations and purchases will be unavailable on this date.
Quick search in Citations
AnywhereCitation
Advanced Search
Trending Terms:
Articles
January 9, 2008

Progranulin genetic variability contributes to amyotrophic lateral sclerosis

K. Sleegers, MD, PhD, N. Brouwers, MSc, S. Maurer-Stroh, PhD, M. A. van Es, MD, P. Van Damme, MD, PhD, P.W.J. van Vught, MSc, J. van der Zee, MSc, S. Serneels, T. De Pooter, M. Van den Broeck, M. Cruts, PhD, J. Schymkowitz, PhD, P. De Jonghe, MD, PhD, F. Rousseau, PhD, L. H. van den Berg, MD, PhD, W. Robberecht, MD, PhD, and C. Van Broeckhoven, PhD, DScAuthors Info & Affiliations
July 22, 2008 issue
71 (4) 253-259
https://doi.org/10.1212/01.wnl.0000289191.54852.75
Letters to the Editor
Get Access

Abstract

Objectives: Null mutations in progranulin (PGRN) cause ubiquitin-positive frontotemporal dementia (FTD) linked to chromosome 17q21 (FTDU-17). Here we examined PGRN genetic variability in amyotrophic lateral sclerosis (ALS), a neurodegenerative motor neuron disease that overlaps with FTD at a clinical, pathologic, and epidemiologic level.
Methods: We sequenced all exons, exon-intron boundaries, and 5′ and 3′ regulatory regions of PGRN in a Belgian sample of 230 patients with ALS. The frequency of observed genetic variants was determined in 436 healthy control individuals. The contribution of eight frequent polymorphisms to ALS risk, onset age, and survival was assessed in an association study in the Belgian sample and a replication series of 308 Dutch patients with ALS and 345 Dutch controls.
Results: In patients with ALS we identified 11 mutations, 5 of which were predicted to affect PGRN protein sequence or levels (four missense mutations and one 5′ regulatory variant). Moreover, common variants (rs9897526, rs34424835, and rs850713) and haplotypes were significantly associated with a reduction in age at onset and a shorter survival after onset of ALS in both the Belgian and the Dutch studies.
Conclusion: PGRN acts as a modifier of the course of disease in patients with amyotrophic lateral sclerosis, through earlier onset and shorter survival.

Get full access to this article

View all available purchase options and get full access to this article.

Get Access

Supplementary Material

File (e-figure_1.pdf)
File (e-figure_2.pdf)
File (e-tables_revised.doc)

REFERENCES

1.
Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B. Are amyotrophic lateral sclerosis patients cognitively normal? Neurology 2003;60:1094–1097.
Crossref
PubMed
Google Scholar
2.
Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 2005;65:586–590.
Crossref
PubMed
Google Scholar
3.
Wightman G, Anderson VE, Martin J, et al. Hippocampal and neocortical ubiquitin-immunoreactive inclusions in amyotrophic lateral sclerosis with dementia. Neurosci Lett 1992;139:269–274.
Crossref
PubMed
Google Scholar
4.
Mackenzie IR, Feldman H. Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. Dement Geriatr Cogn Disord 2004;17:333–336.
Crossref
PubMed
Google Scholar
5.
Mackenzie IR, Feldman HH. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 2005;64:730–739.
Crossref
PubMed
Google Scholar
6.
Arai T, Hasegawa M, Akiyama H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 2006;351:602–611.
Crossref
PubMed
Google Scholar
7.
Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130–133.
Crossref
PubMed
Google Scholar
8.
Majoor-Krakauer D, Ottman R, Johnson WG, Rowland LP. Familial aggregation of amyotrophic lateral sclerosis, dementia, and Parkinson’s disease: evidence of shared genetic susceptibility. Neurology 1994;44:1872–1877.
Crossref
PubMed
Google Scholar
9.
Hosler BA, Siddique T, Sapp PC, et al. Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000;284:1664–1669.
Crossref
PubMed
Google Scholar
10.
Talbot K, Ansorge O. Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. Hum Mol Genet 2006;15 suppl 2:R182–R187.
Crossref
PubMed
Google Scholar
11.
Baker M, Mackenzie IR, Pickering-Brown SM, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006;442:916–919.
Crossref
PubMed
Google Scholar
12.
Cruts M, Gijselinck I, van der ZJ, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 Nature 2006;442:920–924.
Crossref
PubMed
Google Scholar
13.
Bhandari V, Palfree RG, Bateman A. Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains. Proc Natl Acad Sci USA 1992;89:1715–1719.
Crossref
PubMed
Google Scholar
14.
Zhu J, Nathan C, Jin W, et al. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell 2002;111:867–878.
Crossref
PubMed
Google Scholar
15.
Daniel R, He Z, Carmichael KP, Halper J, Bateman A. Cellular localization of gene expression for progranulin. J Histochem Cytochem 2000;48:999–1009.
Crossref
PubMed
Google Scholar
16.
He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med 2003;81:600–612.
Crossref
PubMed
Google Scholar
17.
Ahmed Z, Mackenzie IR, Hutton ML, Dickson DW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation 2007;4:7.
Google Scholar
18.
Malaspina A, Kaushik N, de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem 2001;77:132–145.
Crossref
PubMed
Google Scholar
19.
Tangkeangsirisin W, Serrero G. PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells. Carcinogenesis 2004;25:1587–1592.
Crossref
PubMed
Google Scholar
20.
Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000;155:945–959.
Crossref
PubMed
Google Scholar
21.
Brouwers N, Nuytemans K, van der Zee J, et al. Clinical expression of progranulin in an extended founder family includes Alzheimer and Parkinson diagnoses. Arch Neurol 2007;64:1436–1446.
Crossref
PubMed
Google Scholar
22.
van der Zee J, Rademakers R, Engelborghs S, et al. A Belgian ancestral haplotype harbours a highly prevalent mutation for 17q21-linked tau-negative FTLD. Brain 2006;129:841–852.
Crossref
PubMed
Google Scholar
23.
Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436–446.
Crossref
PubMed
Google Scholar
24.
van der Zee J, Le BI, Maurer-Stroh S, et al. Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia. Hum Mutat 2007;28:416.
Google Scholar
25.
Czaplewski C, Oldziej S, Liwo A, Scheraga HA. Prediction of the structures of proteins with the UNRES force field, including dynamic formation and breaking of disulfide bonds. Protein Eng Des Sel 2004;17:29–36.
Crossref
PubMed
Google Scholar
26.
Cartharius K, Frech K, Grote K, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005;21:2933–2942.
Crossref
PubMed
Google Scholar
27.
Terwilliger J, Ott J. Handbook of Human Genetic Linkage. Baltimore: Johns Hopkins UP; 1994.
Google Scholar
28.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263–265.
Crossref
PubMed
Google Scholar
29.
Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425–434.
Crossref
PubMed
Google Scholar
30.
Majoor-Krakauer D, Willems PJ, Hofman A. Genetic epidemiology of amyotrophic lateral sclerosis. Clin Genet 2003;63:83–101.
Crossref
PubMed
Google Scholar
31.
Ge B, Gurd S, Gaudin T, et al. Survey of allelic expression using EST mining. Genome Res 2005;15:1584–1591.
Crossref
PubMed
Google Scholar
32.
Schymick J, Yang Y, Andersen P, et al. Progranulin mutations and ALS or ALS-FTD phenotypes. J Neurol Neurosurg Psychiatry 2007; 78:754–756.
Crossref
PubMed
Google Scholar
33.
Le Ber I, van der Zee J, Hannequin D, et al. Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 2007;28:846–855.
Crossref
PubMed
Google Scholar
34.
Nelis E, Haites N, Van Broeckhoven C. Mutations in the peripheral myelin genes and associated genes in inherited peripheral neuropathies. Hum Mutat 1999;13:11–28.
Crossref
PubMed
Google Scholar
35.
Chen YZ, Bennett CL, Huynh HM, et al. DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). Am J Hum Genet 2004;74:1128–1135.
Crossref
PubMed
Google Scholar
36.
Duquette A, Roddier K, McNabb-Baltar J, et al. Mutations in senataxin responsible for Quebec cluster of ataxia with neuropathy. Ann Neurol 2005;57:408–414.
Crossref
PubMed
Google Scholar
37.
Moreira MC, Klur S, Watanabe M, et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004;36:225–227.
Crossref
PubMed
Google Scholar
38.
Thein SL. Genetic modifiers of beta-thalassemia. Haematologica 2005;90:649–660.
PubMed
Google Scholar

Information & Authors

Information

Published In

Neurology®
Volume 71 • Number 4 • July 22, 2008
Pages: 253-259
PubMed: 18184915

Copyright

© 2008.

Publication History

Published online: January 9, 2008
Published in print: July 22, 2008

Permissions

Request permissions for this article.

Notes

Authors

Affiliations & Disclosures

K. Sleegers, MD, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
N. Brouwers, MSc
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
S. Maurer-Stroh, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
M. A. van Es, MD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
P. Van Damme, MD, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
P.W.J. van Vught, MSc
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
J. van der Zee, MSc
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
S. Serneels
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
T. De Pooter
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
M. Van den Broeck
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
M. Cruts, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
J. Schymkowitz, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
P. De Jonghe, MD, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
F. Rousseau, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
L. H. van den Berg, MD, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
W. Robberecht, MD, PhD
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author
C. Van Broeckhoven, PhD, DSc
From the Neurodegenerative Brain Diseases Group (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., C.V.B.) and Neurogenetics Group (P.D.J.), Department of Molecular Genetics, and SWITCH Laboratory (S.M.-S., J.S., F.R.) VIB, University of Antwerp (K.S., N.B., J.v.d.Z., S.S., T.D.P., M.V.d.B., M.C., P.D.J., C.V.B.), Antwerpen; University Brussels (VUB) (S.M.-S., J.S., F.R.); Department of Neurology (M.A.v.E., P.W.J.v.V., L.H.v.d.B.), Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, the Netherlands; Division of Neurology (P.V.D., W.R.), University Hospital Gasthuisberg, University of Leuven (KUL); and Division of Neurology (P.D.J.), University Hospital Antwerpen, Belgium.
View all articles by this author

Notes

Address correspondence and reprint requests to Prof. Dr. Christine Van Broeckhoven, Neurodegenerative Brain Diseases Group, VIB–Department of Molecular Genetics, University of Antwerp, Universiteitsplein 1, BE-2610 Antwerpen, Belgium [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
    • Maria A. Boylan,
    • Andrew Pincetic,
    • Gary Romano,
    • Nadine Tatton,
    • Sara Kenkare-Mitra,
    • Arnon Rosenthal,
    Targeting Progranulin as an Immuno-Neurology Therapeutic Approach, International Journal of Molecular Sciences, 24, 21, (15946), (2023).https://doi.org/10.3390/ijms242115946
    Crossref
    • Isabell Cordts,
    • Annika Wachinger,
    • Carlo Scialo,
    • Paul Lingor,
    • Magdalini Polymenidou,
    • Emanuele Buratti,
    • Emily Feneberg,
    TDP-43 Proteinopathy Specific Biomarker Development, Cells, 12, 4, (597), (2023).https://doi.org/10.3390/cells12040597
    Crossref
    • Michael Kurnellas,
    • Ananya Mitra,
    • Tina Schwabe,
    • Robert Paul,
    • Andrew E. Arrant,
    • Erik D. Roberson,
    • Michael Ward,
    • Felix Yeh,
    • Hua Long,
    • Arnon Rosenthal,
    Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia, Journal of Translational Medicine, 21, 1, (2023).https://doi.org/10.1186/s12967-023-04251-y
    Crossref
    • Janice E.A. Braun,
    Extracellular chaperone networks and the export of J-domain proteins, Journal of Biological Chemistry, 299, 2, (102840), (2023).https://doi.org/10.1016/j.jbc.2022.102840
    Crossref
    • Guiwu Huang,
    • Jinlong Jian,
    • Chuan-Ju Liu,
    Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances, Cytokine & Growth Factor Reviews, (2023).https://doi.org/10.1016/j.cytogfr.2023.11.001
    Crossref
    • Babykumari P. Chitramuthu,
    • Víctor R. Campos-García,
    • Andrew Bateman,
    Multiple Molecular Pathways Are Influenced by Progranulin in a Neuronal Cell Model–A Parallel Omics Approach, Frontiers in Neuroscience, 15, (2022).https://doi.org/10.3389/fnins.2021.775391
    Crossref
    • Wei-Ming Su,
    • Xiao-Jing Gu,
    • Qing-Qing Duan,
    • Zheng Jiang,
    • Xia Gao,
    • Hui-Fang Shang,
    • Yong-Ping Chen,
    Genetic factors for survival in amyotrophic lateral sclerosis: an integrated approach combining a systematic review, pairwise and network meta-analysis, BMC Medicine, 20, 1, (2022).https://doi.org/10.1186/s12916-022-02411-3
    Crossref
    • Herve Rhinn,
    • Nadine Tatton,
    • Stella McCaughey,
    • Michael Kurnellas,
    • Arnon Rosenthal,
    Progranulin as a therapeutic target in neurodegenerative diseases, Trends in Pharmacological Sciences, 43, 8, (641-652), (2022).https://doi.org/10.1016/j.tips.2021.11.015
    Crossref
    • Sophia R. L. Vieira,
    • Huw R. Morris,
    Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease, Frontiers in Neurology, 12, (2021).https://doi.org/10.3389/fneur.2021.679927
    Crossref
    • Huan Du,
    • Man Ying Wong,
    • Tingting Zhang,
    • Mariela Nunez Santos,
    • Charlene Hsu,
    • Junke Zhang,
    • Haiyuan Yu,
    • Wenjie Luo,
    • Fenghua Hu,
    A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses, Life Science Alliance, 4, 7, (e202000874), (2021).https://doi.org/10.26508/lsa.202000874
    Crossref
  11. See more

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Save for later Item saved, go to cart
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share

View full text|Download PDF